We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is C4 Therapeutics (CCCC) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has C4 Therapeutics, Inc. (CCCC - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
C4 Therapeutics, Inc. is a member of our Medical group, which includes 913 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. C4 Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for CCCC's full-year earnings has moved 13.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, CCCC has moved about 32.5% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 7.6% on average. This means that C4 Therapeutics, Inc. is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is CareDx (CDNA - Free Report) . The stock has returned 295.8% year-to-date.
For CareDx, the consensus EPS estimate for the current year has increased 113.8% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, C4 Therapeutics, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 448 individual companies and currently sits at #86 in the Zacks Industry Rank. This group has gained an average of 5.7% so far this year, so CCCC is performing better in this area.
In contrast, CareDx falls under the Medical Services industry. Currently, this industry has 70 stocks and is ranked #55. Since the beginning of the year, the industry has moved +6.9%.
Going forward, investors interested in Medical stocks should continue to pay close attention to C4 Therapeutics, Inc. and CareDx as they could maintain their solid performance.
Image: Bigstock
Is C4 Therapeutics (CCCC) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has C4 Therapeutics, Inc. (CCCC - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
C4 Therapeutics, Inc. is a member of our Medical group, which includes 913 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. C4 Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for CCCC's full-year earnings has moved 13.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, CCCC has moved about 32.5% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 7.6% on average. This means that C4 Therapeutics, Inc. is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is CareDx (CDNA - Free Report) . The stock has returned 295.8% year-to-date.
For CareDx, the consensus EPS estimate for the current year has increased 113.8% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, C4 Therapeutics, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 448 individual companies and currently sits at #86 in the Zacks Industry Rank. This group has gained an average of 5.7% so far this year, so CCCC is performing better in this area.
In contrast, CareDx falls under the Medical Services industry. Currently, this industry has 70 stocks and is ranked #55. Since the beginning of the year, the industry has moved +6.9%.
Going forward, investors interested in Medical stocks should continue to pay close attention to C4 Therapeutics, Inc. and CareDx as they could maintain their solid performance.